Jacobson Pharma (HKG:2633) expects its profit from continuing operations to rise over 40% year over year for the year ended March 31, a Monday Hong Kong bourse filing said.
The drugmaker attributed the higher profit mainly to a good performance in the specialty medicines and overall generic drug business, revenue contributions from newly in-licensed products and the launch of new products, and cost controls.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.